Journal of Pediatric Hematology/Oncology · 2004 · 15 citations · 9 references
MedicineOncologyPharmacologyChemotherapyMolecular OncologyPediatric OncologyBone TumorsChemotherapy For Bone SarcomaCytotoxic ChemotherapyMalignant NeoplasmsPediatric ChemotherapyTopoisomerase InhibitorsAcute Myeloid Leukemia TherapyAcute Myeloid Leukemia TreatmentMultiagent ChemotherapyOsteosarcoma ChemotherapyOsteosarcoma TreatmentPlatinum CompoundsSecond Malignant NeoplasmsTopoisomerase Ii Inhibitors
Secondary acute leukemia (SAL) after treatment of osteosarcoma has been seldom reported in children. Two main mechanisms that can induce SAL have been described. The authors describe two patients who developed SAL after treatment with multiagent therapy. The first patient developed a secondary acute leukemia after treatment with alkylating agents and platinum compounds. The second patient had the clinical and molecular features of a secondary acute leukemia due to topoisomerase II inhibitors. The authors also discuss the data regarding cisplatin-associated SAL. Different molecular and pathogenic agents may be implicated in the development of second malignant neoplasms in long-term survivors of osteosarcomas.
9
Risk of Leukemia after Platinum-Based Chemotherapy for Ovarian Cancer
Lois B. Travis, Eric J. Holowaty, Kjell Bergfeldt et al. · New England Journal of Medicine · 1999 · 359 citations · Full text
Medicine, Gynecology, Oncology +14
Myeloid neoplasia in children treated for solid tumours
Elizabeth Thompson, Judith A. Wilimas, Laura C. Bowman et al. · The Lancet · 1990 · 109 citations
Medicine, Oncology, Pediatrics +11
Susanne Viehmann, Andrea Teigler‐Schlegel, Jochen Bruch et al. · Leukemia · 2003 · 95 citations
Medicine, Hematology, Oncology +17